Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SNGX
SNGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNGX News
Soligenix Receives PIM Designation for SGX945 in the UK
1d ago
PRnewswire
Soligenix Receives UK PIM Designation for SGX945
1d ago
Newsfilter
Soligenix Receives Positive EMA Orphan Drug Recommendation
Feb 26 2026
PRnewswire
Soligenix Receives Positive EMA Orphan Drug Recommendation
Feb 26 2026
Newsfilter
Soligenix to Present at BIO Investment Summit
Feb 24 2026
PRnewswire
Soligenix to Present at BIO Investment Summit
Feb 24 2026
Newsfilter
Soligenix Outlines Strategic Vision for 2026
Feb 12 2026
PRnewswire
Soligenix Provides Update on Clinical Trials and Strategic Options
Feb 12 2026
Newsfilter
Soligenix Publishes Positive Phase 2a Results for SGX945 in Behçet's Disease Treatment
Dec 18 2025
PRnewswire
Soligenix Expands Psoriasis Trial, Revealing Improved Results with New Gel
Dec 17 2025
Benzinga
Soligenix Reports Clinical Success of Optimized SGX302 Gel for Psoriasis Treatment
Dec 17 2025
PRnewswire
Soligenix Reaches Enrollment Target for Interim Analysis in Phase 3 Clinical Trial of HyBryte™ for Cutaneous T-Cell Lymphoma Treatment
Nov 19 2025
Newsfilter
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Nov 07 2025
PRnewswire
Soligenix Reaches Key Safety Milestone in Phase 3 Clinical Trial of HyBryte™ for Treating Cutaneous T-Cell Lymphoma
Oct 07 2025
Newsfilter
Soligenix Expands European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Sep 30 2025
Newsfilter
Soligenix Announces Closing of $7.5 Million Public Offering
Sep 29 2025
PRnewswire
Show More News
